myTomorrows, global online facilitator of early access to investigational drugs, has introduced an openly accessible API to open up its comprehensive database of uniform information relating to clinical trials. Data on over 300,000 clinical trials, already accessible via its patient and physician centric website, can now be used by other organisations in their own environments. “Opening the myTomorrows database is a big push forward to make comprehensive and uniform information on clinical trials freely accessible to anybody who needs it. We hope to see further applications grow out of our data to better serve unmet medical needs globally and advance drug development” COO Robert Kraal explains, setting out myTomorrows’ hopes for the development. The interface can be used to search, filter, and download complete historic clinical trial records data accumulated from all the registries of the World Health Organization’s Primary Registry Network of medical trial registration partners. Potential applications include anything from ad-hoc queries by data scientists to patient trial screening to mobile health. “We have built the API with the intention of making it accessible for the largest group of stakeholders. Using a very simple approach, any programmer can directly access the data in a friendly human-readable format and structure” says Sander Nagtegaal, Chief Technical Officer at myTomorrows. For technical details, please visit the official documentation, the API terms of service or reach out to tech@mytomorrows.com directly.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.